about
TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cellsCloning and characterization of the human neural cell adhesion molecule, CNTN4 (alias BIG-2)Growth inhibitory retinoid effects after recruitment of retinoid X receptor beta to the retinoic acid receptor beta promoterThe estrogen-responsive B box protein is a novel regulator of the retinoid signalReduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemiaMRP1 gene expression level regulates the death and differentiation response of neuroblastoma cellsCell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual diseaseABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.The p53 pathway and its inactivation in neuroblastoma.Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells.Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.Mechanism of relapse in pediatric acute lymphoblastic leukemia.Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells.Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells.High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance.MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.ABC transporters in cancer: more than just drug efflux pumps.Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation.High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma.c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells.Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells.ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript.Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.Synergy between 5′ and 3′ flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cellsEvidence that the MYCN oncogene regulates MRP gene expression in neuroblastomaDetermination of N-myc gene amplification in neuroblastoma by differential polymerase chain reactionAbsence of MEN2A- or 2B-typeRETmutations in primary neuroblastoma tumour tissueMacrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in NeuroblastomaN-myc amplification in Wilms' tumor
P50
Q24297046-9B9E8B6A-1C5F-4DA7-8812-EB1351271448Q24298256-94ADA6D0-F417-48DE-AE0A-83774E2D4EC4Q24302705-656993F8-FEAA-4592-A0B5-4510F1EF94ECQ24319942-60FB40E4-C8B2-49FE-A788-43B6A1BF847EQ28240130-ADD45444-7CD2-4382-AEA2-80A27038CE45Q28364926-A2D51F34-F9C9-402C-9D56-9EFEC31D7E23Q34398691-C0E57C19-E91A-4CA2-BEC6-DD2582FE45F5Q34482630-7E011766-7763-4FC1-B865-8CFC85903AEEQ35022780-ED77C510-FC96-4502-A597-FECAFF6EF01FQ35166695-4A14BB45-2416-46ED-8D3F-371526D12B56Q35184948-3AED6F97-C96E-43F6-AC7F-A06F31C136C4Q36276954-CBB1D83D-17A9-461D-BF26-027A53D2FE84Q37080926-FBEFCD25-989E-4D96-8DDF-B2DE3A4F0D7CQ37164456-78D41258-70ED-45C6-B14E-3BE4980FD8DAQ37494210-C6C7C4D0-F0A7-4A10-939C-3E6ECA156EF5Q39793773-908126A7-9BD0-4F6F-90AB-F66AF12A4512Q39990183-3E167D11-675E-4912-9EEF-66631D0269F3Q40101935-C64C4A89-7003-4988-97F4-446C9C6EFC25Q40434177-A0A8CD98-0F53-43A4-948B-1D756F9544A0Q40435926-8119FFB2-85B5-4A0C-9D12-5E71BCA27778Q40666994-550E4FD1-5C80-454C-9398-F6D20DD4DA17Q40687183-449A84DE-2AF5-4038-B922-7F58A6A5529EQ40797616-C7D7386C-01F2-4C95-AAFA-71DD0A0C2457Q42455985-E729E259-17A8-4A59-A498-F2124F3C05E9Q42802882-2C00CBA5-B68E-4704-8142-88461D8B849FQ43193922-B0B0ABC4-6D20-4369-92BD-A7D396830D14Q43512650-16D5746B-8E9A-4D15-A09E-C552C3FF1D06Q43952491-E60EA382-8A7D-4385-A03E-0E8CA6FA2CF8Q44496771-E5F5917C-DA38-405F-A978-F4C957B63318Q50193901-D4D9C033-EE7E-43B5-81C5-B7B24703A735Q53940865-51DFEED7-EE5E-4D5F-AD4E-934F752C1320Q54249661-FC053028-E3C3-43C3-8FB1-8D7BBF7085D7Q54334626-879A956F-41B9-408B-A558-5C9513EAB1EEQ54479075-DE4C074F-5B44-4E73-97F9-D4C8F291F3F7Q57734314-246C5512-1D84-4301-8A7E-46BA65E2BC36Q57734328-5C4111CB-759A-48EA-A6D1-90F8C476BB4AQ58226955-23A940A1-0A8D-4B18-8A89-3684E5DA43ABQ60510131-BFA5BB62-EF8C-4650-8941-04963746A585Q61917630-842B914B-0C89-4614-94E3-172E8C06562FQ69813799-B247893B-8D1F-4277-AE86-E797F80E93BE
P50
description
researcher
@en
name
M D Norris
@ast
M D Norris
@en
M D Norris
@nl
type
label
M D Norris
@ast
M D Norris
@en
M D Norris
@nl
prefLabel
M D Norris
@ast
M D Norris
@en
M D Norris
@nl
P106
P31
P496
0000-0002-0632-4589